Clinical Calculators
Weight-based dosing, pediatric calculators, renal adjustment, and unit converters for clinical use.
For Healthcare Professionals: These tools are intended as clinical references and decision support. Always verify calculations and consult current medicine labeling, clinical pharmacist, or authoritative references before prescribing or administering medications.
Calculate Body Mass Index and Body Surface Area (Mosteller formula) for dose planning.
Example
BSA used for chemotherapy dosing. BMI for obesity-based adjustments.
Calculate mg/kg doses for children with a maximum dose cap. Supports multiple common medicines.
Example
Amoxicillin: 25–45 mg/kg/day. Max single dose: 500 mg.
Cockcroft-Gault CrCl + KDIGO staging. Guides dose reduction for renally-cleared medicines.
Example
Metformin: contraindicated if eGFR <30 mL/min/1.73m².
Convert mcg/kg/min ↔ mL/hr for continuous infusions like dopamine, norepinephrine, heparin.
Example
Dopamine 400mg/250mL at 5 mcg/kg/min for 70 kg = 13.1 mL/hr.
Calculate CDC oral morphine milligram equivalents for multi-opioid regimens. Essential for prescribing safety.
Example
Oxycodone 10mg + codeine 30mg = 18 MME/day total.
Check interactions between up to 8 medications simultaneously using our curated medicine database.
Example
Warfarin + Aspirin = Major (increased bleeding risk).
| Medicine | Indication | Dose | Route | Frequency | Renal Adjustment |
|---|---|---|---|---|---|
| Amoxicillin | Acute otitis media (pediatric) | 80–90 mg/kg/day | Oral | Divided q12h | Reduce if CrCl < 30 |
| Ibuprofen | Fever / pain (pediatric) | 5–10 mg/kg/dose | Oral | q6–8h | Avoid if eGFR < 30 |
| Acetaminophen | Pain / fever (adult) | 325–1000 mg/dose | Oral/IV | q4–6h | No adjustment |
| Metformin | Type 2 diabetes | 500–1000 mg/dose | Oral | BID–TID with meals | Hold if eGFR < 30 |
| Lisinopril | Hypertension | 10–40 mg/day | Oral | Once daily | Start low, titrate cautiously |
| Vancomycin | Serious gram+ infections | 15–20 mg/kg/dose | IV | q8–12h (AUC-guided) | Extend interval based on CrCl |
Pharmacotherapy is a precise science — the difference between a therapeutic dose and a toxic dose can be narrow, and the optimal dose varies significantly between patients based on age, weight, organ function, genetic factors, and co-administered medications. Understanding dosing principles is fundamental to safe, effective medication use.
The therapeutic index (TI) is the ratio between the toxic dose and the effective dose (TD50/ED50). Medicines with a narrow therapeutic index — such as warfarin, digoxin, lithium, vancomycin, aminoglycosides, and phenytoin — require careful dose titration and therapeutic medicine monitoring (TDM) because the difference between under-dosing and overdosing is clinically significant.
For narrow TI medicines, population-based dosing is insufficient — individualized pharmacokinetic dosing using measured medicine levels (trough concentrations, AUC-based monitoring) is standard of care.
Children are not small adults. Medicine metabolism, distribution, and elimination differ substantially across developmental stages: neonates (0–28 days), infants (1–12 months), children (1–12 years), and adolescents. Neonates have immature hepatic and renal function; infants have higher total body water relative to adults; children often have higher weight- normalized clearance rates requiring higher mg/kg doses for some medicines.
Young's Rule and Clark's Rule (fraction of adult dose based on age or weight) are outdated empirical approaches. Modern pediatric dosing is evidence-based, using published pediatric pharmacokinetic data when available. The FDA Pediatric Research Equity Act (PREA) now requires pediatric studies for many new medicines.
The kidneys eliminate most medicines, either unchanged or as metabolites. When kidney function is impaired, renally cleared medicines accumulate, increasing the risk of toxicity. The standard clinical tool is the Cockcroft-Gault equation, which estimates creatinine clearance from serum creatinine, age, weight, and sex.
Dose adjustment strategies include: reducing the individual dose (same frequency), extending the dosing interval (same dose), or both. The choice depends on whether maintaining continuous medicine exposure or avoiding high peak concentrations is more important. For aminoglycosides, extended interval dosing (once-daily high dose) exploits concentration-dependent killing; for beta-lactam antibiotics, maintaining continuous medicine levels above the MIC is the goal.
Hepatic impairment affects medicine metabolism, protein binding, and first-pass effect. The Child-Pugh score (assessing bilirubin, INR, albumin, ascites, encephalopathy) provides a clinical staging framework (A/B/C) used in many medicine labeling sections. However, Child-Pugh has limitations — a quantitative tool like the MELD score may better predict hepatic metabolizing capacity in some settings.
For medicines with long half-lives where reaching therapeutic levels quickly is important, a loading dose is given. The loading dose is calculated based on the volume of distribution (Vd): Loading dose = Target concentration × Vd. Maintenance doses maintain steady-state by replacing medicine eliminated per dosing interval. Understanding this distinction is critical for medicines like digoxin, phenytoin, amiodarone, and vancomycin.
Weight-based dosing (mg/kg) ensures that each patient receives a dose proportional to their body mass, which is essential for medicines with narrow therapeutic indices, in pediatric patients, and for medicines eliminated by the kidneys or liver. Using a flat dose in populations with widely varying weights risks under-dosing (treatment failure) or overdosing (toxicity).
The most widely used method is the Cockcroft-Gault equation: CrCl (mL/min) = (140 - age) × weight in kg / (72 × serum creatinine in mg/dL), multiplied by 0.85 for females. This estimates kidney function to guide dose adjustments for renally eliminated medicines. Note that this formula may overestimate CrCl in obese patients; ideal body weight or adjusted body weight should be used.
eGFR (estimated glomerular filtration rate) is calculated using the CKD-EPI or MDRD equation and is normalized to body surface area (mL/min/1.73m²). CrCl from Cockcroft-Gault is not normalized and gives absolute mL/min. For medicine dosing, most pharmacokinetic studies used CrCl (Cockcroft-Gault), so this formula is preferred for dose adjustments, though many clinical labs report eGFR.
Unlike renal impairment, there is no simple formula for hepatic dose adjustment. Clinical scales like Child-Pugh score (A/B/C) are used for medicines primarily metabolized by the liver. For Child-Pugh C (severe) impairment, dose reductions of 25–75% may be needed. Medicine prescribing information typically specifies hepatic dose adjustments when relevant.
Accurate medication dosing is one of the most fundamental aspects of clinical practice. Errors in dosing represent a leading cause of medication-related adverse events, accounting for billions of dollars in healthcare costs and significant patient harm each year. The MedCentralHub Dosage Tools suite provides validated clinical calculators based on evidence-based formulas used in modern medical practice. These tools are designed to support healthcare professionals in making accurate dosing decisions while complementing — not replacing — clinical judgment and current medication labeling.
Medication dosing involves multiple considerations that must be balanced for each individual patient. Drug efficacy depends on achieving therapeutic concentrations at the target site, while drug safety requires avoiding toxic concentrations. The therapeutic index — the ratio between toxic and effective doses — varies dramatically across medications. Some drugs (like acetaminophen) have wide therapeutic windows allowing flexible dosing, while others (warfarin, digoxin, lithium, methotrexate) have narrow therapeutic indices requiring precise dosing and monitoring.
Key pharmacokinetic factors that affect dosing include absorption (bioavailability), distribution (volume of distribution, protein binding), metabolism (primarily hepatic via cytochrome P450 enzymes), and elimination (primarily renal). Each of these parameters can be altered by patient-specific factors including age, weight, organ function, genetics, drug interactions, and disease states. The art and science of clinical dosing involves accounting for all these variables to achieve optimal therapeutic outcomes.
Weight-based dosing (mg/kg) is the standard approach for pediatric patients and many adult medications. This method recognizes that drug requirements often correlate with body size — larger patients generally need higher absolute doses to achieve the same concentration. However, weight-based dosing has limitations: the relationship between weight and drug response is not always linear, and dosing based on actual body weight in obese patients can lead to overdosing for hydrophilic drugs that don't distribute into adipose tissue.
Multiple body weight descriptors exist for clinical use: actual body weight (ABW), ideal body weight (IBW) calculated from height and gender, adjusted body weight (AdjBW) for obese patients, and lean body weight (LBW). The choice depends on the medication's pharmacokinetic characteristics and clinical context. Aminoglycosides, for example, are typically dosed using adjusted body weight in obese patients, while vancomycin uses actual body weight.
BSA-based dosing (mg/m²) is preferred for many oncology medications, some immunosuppressants, and certain antibiotics. The Mosteller formula (BSA = √(height in cm × weight in kg / 3600)) is most commonly used clinically due to its simplicity and accuracy. BSA correlates better than weight with metabolic rate, cardiac output, and glomerular filtration rate, making it more consistent across patient sizes.
BSA dosing has particular importance in chemotherapy where the therapeutic window is narrow and overdosing can be lethal. However, BSA dosing also has limitations — it overestimates dose requirements in obese patients and may be less accurate at extremes of size. Many oncology protocols now incorporate dose-banding (using standardized doses for ranges of BSA) to reduce calculation errors.
Kidney function is critical for many medication dosing decisions. The kidneys eliminate many drugs and their metabolites, so renal impairment can lead to dangerous drug accumulation. The Cockcroft-Gault formula estimates creatinine clearance (CrCl) from serum creatinine, age, weight, and gender. The KDIGO classification stages chronic kidney disease based on estimated glomerular filtration rate (eGFR), with specific medication adjustments recommended at each stage.
Medications requiring renal adjustment include many antibiotics (aminoglycosides, vancomycin, beta-lactams), anticoagulants (LMWH, DOACs), pain medications (morphine, gabapentin), and cardiovascular drugs (digoxin, ACE inhibitors). Acute kidney injury complicates dosing because creatinine takes time to equilibrate with changing kidney function. In rapidly changing renal function, more frequent monitoring and adjustment may be needed.
Liver disease affects medication clearance for many drugs, particularly those metabolized by hepatic enzymes. Unlike renal function where creatinine provides a quantitative measure, hepatic clearance is harder to predict from standard liver function tests. The Child-Pugh score (based on bilirubin, albumin, INR, ascites, and encephalopathy) classifies liver disease severity and guides dosing decisions.
Medications particularly affected by liver disease include benzodiazepines (use shorter-acting agents like lorazepam), opioids (start with lower doses), statins (potential hepatotoxicity), warfarin (increased anticoagulant effect), and many others. Some medications should be avoided entirely in severe liver disease — for example, methotrexate, valproic acid, and certain statins.
Pediatric dosing requires special attention because children are not just small adults — they have different physiology, developing organ systems, and varied responses to medications. Neonates have particularly unique pharmacokinetics with immature liver enzymes, reduced renal function, low protein binding, and high body water content. As children mature, their drug handling progressively approaches adult patterns.
Pediatric dose calculations typically use weight-based formulas (mg/kg/dose or mg/kg/day) with maximum dose caps. Age-based dosing is also used for certain medications. The MedCentralHub Pediatric Weight-Based Dosing Calculator implements evidence-based dosing for common pediatric medications including antibiotics, analgesics, and antiepileptics.
Older adults often require lower medication doses than younger adults due to age-related changes in pharmacokinetics. Decreased renal function (estimated GFR declines by ~1 mL/min/year after age 40), reduced hepatic metabolism, decreased lean body mass, and altered protein binding all affect drug handling. Polypharmacy is common in older adults, increasing interaction risks.
The Beers Criteria (American Geriatrics Society) identifies medications that may be inappropriate for older adults due to safety concerns. Examples include long-acting benzodiazepines, anticholinergic medications, and certain antihypertensives. When prescribing for older adults, the principle of "start low, go slow" applies — beginning with lower doses and titrating gradually based on response.
Converting between opioids requires careful calculation using validated equianalgesic conversion tables. Different opioids have different potencies relative to morphine, and conversion factors are based on parenteral morphine equivalence. Cross-tolerance is incomplete between opioids, so dose reductions (typically 25-50%) are recommended when switching agents to account for individual variation in response.
The Morphine Milligram Equivalent (MME) is the standard unit for comparing opioid doses across medications. CDC guidelines emphasize MME-based risk stratification: doses ≥50 MME/day warrant additional precautions, while doses ≥90 MME/day require careful evaluation and often specialist consultation. Our Morphine Equivalent Calculator implements current MME conversion factors for safe opioid prescribing.
Intravenous medication calculations involve multiple variables: drug concentration, infusion rate (mL/hr or drops/min), total volume to be infused, and time period. Errors in these calculations can result in dangerous over- or under-dosing. The MedCentralHub IV Drip Rate Calculator provides validated formulas for various clinical scenarios including continuous infusions, weight-based infusions (mcg/kg/min), and traditional gravity-fed drip rates with various drop factors.
Specific populations have unique dosing considerations. Pregnancy alters drug pharmacokinetics significantly — increased CYP3A4 activity, increased renal clearance, expanded volume of distribution, and decreased protein binding. Many medications require dose adjustments during pregnancy. Critically ill patients in ICU settings have rapidly changing pharmacokinetics due to multiple factors including organ dysfunction, fluid shifts, and concurrent medications.
Patients with cystic fibrosis often require higher doses of many medications due to enhanced clearance. Obese patients require careful consideration of body weight descriptors. Transplant recipients on immunosuppression require precise dosing to balance organ rejection risk against medication toxicity. Each population requires specialized knowledge to optimize medication therapy.
Modern electronic health records often include automated dose calculation tools, but these systems have limitations and require professional verification. Independent double-checks for high-risk medications, standardized calculation methods, clear units of measurement, and ongoing professional education all contribute to medication safety. The MedCentralHub Dosage Tools complement these institutional safety measures by providing easily accessible, validated calculators that healthcare professionals can use for quick reference and double-checking.
Always remember: clinical judgment cannot be replaced by automated tools. These calculators provide computational support, but the clinician's responsibility for verifying calculations, considering individual patient factors, and making final dosing decisions remains paramount. When in doubt about a calculation or dosing decision, consult with a clinical pharmacist or appropriate specialist for guidance.